levetiracetam
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alcoholism
Conditions
Alcoholism, Generalized Anxiety Disorder, Panic Disorder, Social Phobia, Anxiety Disorders
Trial Timeline
Mar 1, 2004 → Jan 1, 2008
NCT ID
NCT00141115About levetiracetam
levetiracetam is a phase 2 stage product being developed by UCB for Alcoholism. The current trial status is completed. This product is registered under clinical trial identifier NCT00141115. Target conditions include Alcoholism, Generalized Anxiety Disorder, Panic Disorder.
What happened to similar drugs?
4 of 9 similar drugs in Alcoholism were approved
Approved (4) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03340064 | Phase 3 | Completed |
| NCT01618877 | Phase 1 | Completed |
| NCT01407523 | Phase 2 | Completed |
| NCT01398956 | Phase 3 | Completed |
| NCT01292837 | Phase 3 | Completed |
| NCT01063764 | Phase 3 | Completed |
| NCT00505934 | Phase 2 | Completed |
| NCT00627133 | Phase 2 | Withdrawn |
| NCT00535392 | Phase 2 | Completed |
| NCT00376766 | Phase 3 | Terminated |
| NCT00361010 | Pre-clinical | Completed |
| NCT01318408 | Approved | Completed |
| NCT00367432 | Phase 3 | Completed |
| NCT00291655 | Phase 3 | Completed |
| NCT00324454 | Phase 2 | Completed |
| NCT00319605 | Pre-clinical | Completed |
| NCT00307450 | Approved | Completed |
| NCT00279617 | Phase 3 | Completed |
| NCT00325182 | Approved | Completed |
| NCT00252954 | Approved | Completed |
Competing Products
18 competing products in Alcoholism